Immunocore Holdings plc (NASDAQ:IMCR) Shares Purchased by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA increased its position in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 27.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 498,221 shares of the company's stock after acquiring an additional 107,656 shares during the quarter. Massachusetts Financial Services Co. MA owned about 1.00% of Immunocore worth $15,510,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Exchange Traded Concepts LLC boosted its holdings in Immunocore by 40.4% in the third quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company's stock worth $158,000 after acquiring an additional 1,461 shares in the last quarter. Tidal Investments LLC acquired a new position in Immunocore during the 1st quarter valued at approximately $423,000. Connective Portfolio Management LLC acquired a new stake in shares of Immunocore during the third quarter worth $218,000. DNB Asset Management AS increased its position in shares of Immunocore by 35.0% in the 2nd quarter. DNB Asset Management AS now owns 7,211 shares of the company's stock valued at $244,000 after acquiring an additional 1,868 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in Immunocore by 69.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company's stock worth $231,000 after acquiring an additional 3,053 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company's stock.

Immunocore Price Performance

Shares of IMCR stock traded down $0.34 during trading hours on Tuesday, hitting $32.45. 373,576 shares of the company's stock were exchanged, compared to its average volume of 512,293. The firm has a 50 day moving average of $32.27 and a two-hundred day moving average of $36.98. Immunocore Holdings plc has a fifty-two week low of $29.72 and a fifty-two week high of $76.98. The firm has a market cap of $1.62 billion, a P/E ratio of -34.16 and a beta of 0.72. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.50. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The business had revenue of $80.25 million for the quarter, compared to the consensus estimate of $78.94 million. During the same period last year, the firm posted ($0.59) earnings per share. The company's revenue was up 23.7% compared to the same quarter last year. Sell-side analysts forecast that Immunocore Holdings plc will post -0.94 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on IMCR shares. Barclays reduced their price objective on Immunocore from $92.00 to $66.00 and set an "overweight" rating for the company in a research note on Friday, August 9th. HC Wainwright restated a "buy" rating and set a $100.00 price objective on shares of Immunocore in a research note on Thursday, October 24th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Immunocore in a research note on Monday, September 9th. Morgan Stanley decreased their target price on shares of Immunocore from $80.00 to $74.00 and set an "overweight" rating for the company in a research report on Friday, October 11th. Finally, UBS Group assumed coverage on Immunocore in a research report on Thursday, October 24th. They set a "sell" rating and a $24.00 price target on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $69.18.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.